97063 ⎘
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Receptors; Cell surface antigens; Cell surface determinants for hormones
Sub-classes:ERT2 MUTANTS, INDUCIBLE CELL DEATH SYSTEMS, AND USES THEREOF
#2INDUCIBLE CHIMERIC CYTOKINE RECEPTORS
#3METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS
#4NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF
#5ICAM-1 TARGETED CAR CONSTRUCTS AND METHODS OF TREATMENT
#6INHIBITORS OF COMPLEMENT FACTOR H
#7LONG-ACTING GLP-1/GLP-2 DUAL AGONIST COMPOUND
#8NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF
#9CHIMERIC CD40 POLYPEPTIDES AND METHODS OF USE IN IMMUNOTHERAPY
#10HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF
#11HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
#12PHARMACEUTICAL FORMULATION FOR TREATMENT OF CEREBRAL STROKE
#13GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE
#14C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION
#15Inhibitors of complement factor H
#16NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF
#17GIP/GLP1/GCG TRI-RECEPTOR AGONISTS AND USES THEREOF
#18METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS
#19VASOACTIVE INTESTINAL PEPTIDE (VIP) RECEPTOR ANTAGONISTS
#20ANTIBODY-CONJUGATED NANOPARTICLES AND MEDICAL USES THEREOF
#21POLYPEPTIDES WITH ALTERED BINDING TO NEONATAL FC RECEPTOR (FCRN) AND METHODS OF USE
#22LACTAM-MODIFIED POLYPEPTIDE COMPOUNDS
#23NOVEL TRIPLE AGONIST HAVING ACTIVITIES ON ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS AND USE THEREOF
#24NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE
#25OVEREXPRESSION OF INSULIN-LIKE GROWTH FACTOR RECEPTOR MUTANTS TO MODULATE IGF SUPPLEMENTATION
#26NUCLEIC ACID THAT INTERACTS WITH A RECEPTOR FOR ENDOCRINE DISRUPTING CHEMICALS AND USE THEREOF
#27Cells expressing recombinant growth factor receptors
#28COMPOSITION FOR PREVENTION OR TREATMENT OF HYPERLIPIDEMIA COMPRISING TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF AND METHOD USING THE SAME
#29SOLUBLE ACE2 FOR TREATMENT OF COVID-19
#30ANTI-PACAP ANTIBODIES AND USES THEREOF
#31DETECTION OF NOVEL DEGRADATION-RELATED INTERACTIONS
#32CHIMERIC RECEPTOR SENSORS
#33MODIFIED IMMUNE CELL AND USE THEREOF
#34IMMUNOGLOBULIN FC CONJUGATE WHICH MAINTAINS BINDING AFFINITY OF IMMUNOGLOBULIN FC FRAGMENT TO FCRN
#35GLYCOPEPTIDE ANALOGS OF SECRETIN FAMILY PEPTIDES
#36COMPOSITIONS AND METHODS FOR PROMOTING HEMATOPOIETIC CELL CYTOTOXICITY
#37POLYPEPTIDE-FC CONJUGATE WITH ATTENUATED IMMUNE RESPONSE
#38C-carbon linked glutarimide degronimers for target protein degradation
#39Neuroreceptor compositions and methods of use
#40VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR
#41DIMER IMMUNOADHESIN, PHARMACEUTICAL COMPOSTION AND USE THEREOF
#42FUSION PROTEIN OF ETA ANTIBODY AND TGF-BETA TRAP AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF
#43COMPOSITIONS AND METHODS OF TREATMENT FOR BREAST CANCER INVOLVING A NOVEL CAPER?-MLL1 COMPLEX
#44Estrogen receptor mutations and uses thereof
#45PARATHYROID HORMONE FUSION POLYPEPTIDE
#46CONDITIONALLY ACTIVE HETERODIMERIC POLYPEPTIDES AND METHODS OF USE THEREOF
#47Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
#48NUCLEIC ACIDS ENCODING ANCHOR MODIFIED ANTIBODIES AND USES THEREOF
#49DUAL CHIMERIC ANTIGEN RECEPTOR TARGETING EPCAM AND ICAM-1
#50METHODS FOR DOSING AN ACTRIIB ANTAGONIST AND MONITORING OF TREATED PATIENTS
#51CELLS EXPRESSING PARATHYROID HORMONE 1 RECEPTOR AND USES THEREOF
#52SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
#53SSTR-TARGETED CONJUGATES AND PARTICLES AND FORMULATIONS THEREOF
#54COMBINATION THERAPY
#55Method of treatment with a fusion protein comprising apelin and an anti-APLNR antibody
#56Methods of inhibiting complement factor H (CFH) comprising administering an antibody that binds CFH
#57METHOD FOR PREVENTING OR TREATING HEART FAILURE BY ADMINISTERING A MEDICAMENT CONTAINING AN ANTAGONIST OF CORTICOTROPIN RELEASING HORMONE RECEPTOR 2 (CRHR2)
#58Anti-Follicule Stimulating Hormone Receptor Antibodies
#59A Method to Specifically Stimulate Survival and Expansion of Genetically-Modified Immune Cells
#60CHIMERIC ORTHOGONAL RECEPTOR PROTEINS AND METHODS OF USE
#61Fusion protein comprising thyrotropin receptor variants and use thereof
#62Treatment of headache, migraine and/or photophobia conditions using humanized anti-PACAP antibodies
#63COMPOSITIONS AND METHODS FOR TREATING MELANOMA WITH A CHIMERIC ANTIGEN RECEPTOR
#64ENGINEERED CELLS, AND METHODS OF USING THE SAME
#65METHODS FOR DOSING AN ACTIVIN-ACTRIIA ANTAGONIST AND MONITORING OF TREATED PATIENTS
#66Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof
#67ADIPONECTIN-EXPRESSING REGULATORY T-CELL PRECURSORS, COMPOSITION AND METHODS THEREOF
#68HER-1, HER-3 AND IGF-1R COMPOSITIONS AND USES THEREOF
#69Natriuretic peptide receptor 1 antibodies and methods of use
#70METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS
#71GENETIC MARKERS AND USES THEREFOR
#72METHODS FOR DOSING AN ACTRIIB ANTAGONIST AND MONITORING OF TREATED PATIENTS
#73NARCOLEPSY-SPECIFIC MARKERS
#74Materials and Methods for Producing Animals With Short Hair
#75Generation of human pluripotent stem cell derived functional beta cells showing a glucose-dependent mitochondrial respiration and two-phase insulin secretion response
#76Humanized anti-PACAP antibodies
#77Humanized anti-PACAP antibodies
#78Humanized anti-PACAP antibodies
#79Parathyroid hormone fusion polypeptide
#80Recombinant vector comprising ERT2 fused to CAS9
#81VARIANTS DERIVED FROM ACTRIIB AND USES THEREFOR
#82Compositions and methods for treating and/or preventing pathogenic fungal infection and for maintenance of microbiome commensalism
#83METHODS AND COMPOSITIONS FOR TREATING HPA HYPERACTIVITY
#84Anti-complement factor H antibodies
#85Inducible chimeric cytokine receptors
#86SSTR-targeted conjugates and particles and formulations thereof
#87NOVEL IGFR-LIKE RECEPTOR AND USES THEREOF
#88NOVEL ESTROGEN RECEPTOR MUTATIONS AND USES THEREOF
#89Anti-PACAP antibodies and uses thereof
#90PAC1 antibodies and uses thereof
#91HER-1, HER-3 and IGF-1R compositions and uses thereof
#92Fusion protein comprising apelin and an anti-APLNR antibody
#93Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2)
#94Genetically-mutated bacterial strain for detecting estrogenic compound and method for detecting estrogenic compound using the same
#95FUSION POLYPEPTIDE COMPRISING THE EXTRACELLULAR BINDING DOMAIN OF GROWTH HORMONE RECEPTOR
#96C3-carbon linked glutarimide degronimers for target protein degradation
#97Method for treating pathological angiogenesis by administering an antibody that inhibits APLNR
#98Synthetic promoters and uses thereof
#99Vector
#100Endothelin-1 receptor based endothelin-1 sponge
#101Compositions and methods for modulating AT2R activity
#102Estrogen receptor mutations and uses thereof
#103Method of treating Alzheimer's disease
#104Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors
#105Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1
#106SSTR-targeted conjugates and particles and formulations thereof
#107Methods of treating PRLR positive breast cancer
#108Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
#109STABILIZED POLYPEPTIDE INSULIN RECEPTOR MODULATORS
#110Ruthenium and Indium Binding to Gastrins
#111Cells expressing parathyroid hormone 1 receptor and uses thereof
#112METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES
#113Methods for production of functional beta cells
#114Conditionally active heterodimeric polypeptides and methods of use thereof
#115Anti-PACAP antibodies and uses thereof
#116Humanized anti-PACAP antibodies and uses thereof
#117Blood glucose lowering compound
#118Methods for improving cardiac function by administering an antibody that activates APLNR
#119Soluble monomeric anti-Mullerian hormone receptor type II fusion proteins and uses thereof
#120Use of negative functional modulators of erythropoietin for therapy
#121Antagonists for abdominal vasopressin V2 receptor and uses thereof
#122APLNR modulators and uses thereof
#123Variants derived from ActRIIB and uses therefor
#124Growth hormone fusion proteins with growth hormone receptor agonist activity
#125Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
#126Anti-Complement factor H antibodies
#127METHODS FOR DOSING AN ACTIVIN-ACTRIIA ANTAGONIST AND MONITORING OF TREATED PATIENTS
#128METHODS FOR DOSING AN ACTRIIB ANTAGONIST AND MONITORING OF TREATED PATIENTS
#129Genetic markers and uses therefor
#130Stabilized polypeptide insulin receptor modulators
#131IMMUNOGLOBULIN FC CONJUGATE WHICH MAINTAINS BINDING AFFINITY OF IMMUNOGLOBULIN FC FRAGMENT TO FCRN
#132Estrogen receptor mutations and uses thereof
#133Growth hormone secretagogue receptor based protein
#134Materials and methods for producing animals with short hair
#135Selective inhibitor of angiotensin II
#136HER-1, HER-3 and IGF-1R compositions and uses thereof
#137Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
#138Complex-formation-modulating agents and uses therefor
#139Artificial bioluminescent enzyme
#140Antibody modulators of APLNR
#141STABILIZED POLYPEPTIDE INSULIN RECEPTOR MODULATORS
#142Follistatin fusion proteins and uses thereof
#143TRANSGENIC MOUSE MODELS FOR MC4R
#144ANTAGONISTS FOR ABDOMINAL VASOPRESSIN V2 RECEPTOR AND USES THEREOF
#145Growth hormone receptor antagonists
#146Regulation of specific spinal neurons regulating pain transmission via chimeric toxins
#147Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
#148Antibodies to insulin-like growth factor I receptor
#149USE OF NOVEL CYTOKINE RECEPTORS AS BIOMARKERS AND THERAPEUTIC TARGETS IN HUMAN CANCER
#150Antibodies that bind to adrenomedullin and to adrenomedullin receptors and the uses thereof as drugs
#151Parathyroid hormone receptor activation and stem and progenitor cell expansion
#152Methods for treatment of nephrotic syndrome and related conditions
#153Methods for making proteins containing free cysteine residues
#154Method for the treatment of obesity
#155Variants derived from ActRIIB
#156Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
#157Modulation of growth hormone receptor expression and insulin-like growth factor expression
#158Use of cytokine receptors as biomarkers and therapeutic targets in human cancer
#159METHOD OF TREATING NEURODEGENERATIVE DISEASE
#160INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY
#161GLUCAGON-LIKE PROTEIN-1 RECEPTOR (GLP-1R) AGONISTS FOR TREATING AUTOIMMUNE DISORDERS
#162Structure of the C-terminal region of the insulin receptor α-chain and of the insulin-like growth factor receptor α-chain
#163Truncated somatostatin receptors
#164Methods for making proteins containing free cysteine residues
#165INHIBITION OF MIGRATION INHIBITORY FACTOR IN THE TREATMENT OF DISEASES INVOLVING CYTOKINE-MEDIATED TOXICITY
#166Adiponectin receptor and gene encoding the same
#167VEGF antibodies comprising modular recognition domains
#168Multispecific antibody targeting and multivalency through modular recognition domains
#169Antibodies to insulin-like growth factor I receptor
#170PTHR1 RECEPTOR COMPOUNDS
#171Methods of identifying adipocyte specific genes, the genes identified, and their uses
#172Use of cytokine receptors as biomarkers and therapeutic targets in human cancer
#173Therapeutic uses of monoclonal antibodies to the angiotensin-II type 1 receptor
#174Methods for decreasing leptin levels or activity for treating inflammation
#175GLP-1 FUSION POLYPEPTIDES
#176INSULIN FUSION POLYPEPTIDES
#177Parathyroid hormone receptor activation and stem and progenitor cell expansion
#178SYNTHETIC ANALOGS OF THE JUXTAMEMBRANE DOMAIN OF IGF1R AND USES THEREOF
#179NOVEL GPR101 TRANSGENIC MICE AND METHODS OF USE THEREOF
#180INSULIN-LIKE GROWTH FACTOR FUSION PROTEINS
#181CYTOKINE RECEPTOR MODULATORS AND USES THEREOF
#182TREATMENT AND PREVENTION OF CANCEROUS AND PRE-CANCEROUS CONDITIONS OF THE LIVER, LUNG AND ESOPHAGUS
#183Variants derived from ActRIIB and uses therefor
#184Method of promoting apoptosis of differentiated adipocytes and increasing endogenous expression of SFRP-5 peptide by administration of SFRP-5 peptide
#185IGF-1R BINDING PROTEINS AND ANTAGONISTS
#186Fusion protein comprising a Caspase domain and a nuclear hormone receptor binding domain and methods and uses thereof
#187Pharmaceutically Active Insulin Receptor-Modulating Molecules
#188Structure of the insulin receptor ectodomain
#189High throughput assays for inhibitors and activators of PAQR receptors
#190Antibodies to insulin-like growth factor I receptor
#191Constitutively active mutants of the prolactin receptor
#192NATRIURETIC COMPOUNDS, CONJUGATES, AND USES THEREOF
#193Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza
#194Galanin Receptors and Brain Injury
#195Method for determining MIF content
#196CHO CELL
#197NUCLEIC ACID ENCODING A NOVEL DP RECEPTOR PROTEIN AND METHODS OF USE THEREOF
#198METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN COUNTS
#199Parathyroid hormone receptor activation and stem and progenitor cell expansion
#200USE OF NOVEL CYTOKINE RECEPTORS AS BIOMARKERS AND THERAPEUTIC TARGETS IN HUMAN CANCER
#201Adiponectin receptor and gene encoding the same
#202Methods for making proteins containing free cysteine residues
#203Methods for dosing an activin-actriia antagonist and monitoring of treated patients
#204Methods for dosing an actriib antagonist and monitoring of treated patients
#205Sensitive and rapid methods of using chimeric receptors to identify autoimmune disease and assess disease severity
#206Androgen Receptor Related Methods for Treating Bladder Cancer
#207GROWTH FACTOR
#208METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC OUTBREAKS USING REPLIKIN COUNT CYCLES
#209Rhesus monkey Nur77
#210Cloning and expression of gonadotropin-releasing hormone (GnRH) receptors
#211Modified Fusion Polypeptides
#212Polymorphic GHSR nucleic acids and uses thereof
#213Skin Repair Accelerating Therapeutic Agent Containing Ghrelin and Derivatives Thereof or Substance Acting On GHS-R1a as Active Ingredient
#214Nucleic acid molecules encoding prostaglandin receptor proteins
#215MAMMALIAN GALANIN RECEPTORS
#216Growth hormone secretagogues
#217MODULATION OF INSULIN LIKE GROWTH FACTOR I RECEPTOR EXPRESSION
#218Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
#219MAMMALIAN GALANIN RECEPTORS
#220Fusion protein comprising growth hormone and growth hormone receptor
#221Cytokine receptor modulators and uses thereof
#222Synthetic replikin peptides against pathogenic infection of invertebrates in aquaculture
#223Variants derived from ActRIIB and uses therefor
#224Therapeutic uses of factors which inhibit or neutralize MIF activity
#225Peptides for Use in the Treatment of Obesity
#226Cell Penetrating Peptides
#227Adiponectin receptor variant, AdipoR2v2
#228Methods of modifying polypeptides comprising non-natural amino acids
#229Methods and compositions for identifying RNA-binding proteins
#230Human endothelin receptor
#231Amino acid substituted molecules
#232Galanin Receptors and Brain Injury
#233Prostaglandin receptor protein
#234Parathyroid hormone receptor activation and stem and progenitor cell expansion
#235Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
#236Mammalian galanin receptors
#237Cloning and expression of gonadotropin-releasing hormone (GnRH) receptors
#238Methods of identifying adipocyte specific genes, the genes identified, and their uses
#239Transgenic mice containing TRP gene disruptions
#240Methods for production of receptor and ligand isoforms
#241Fusion proteins based upon somatostatin receptors
#242In vivo odorant receptor systems and their uses
#243PTH receptor and screening assay utilizing the same
#244Orthogonal gene switches
#245Use of anti-prolactin agents to treat proliferative conditions
#246Adiponectin receptor and gene encoding the same
#247Methods of modulating bone growth, bone remodeling and adiposity
#248GLP-2 receptor gene promoter and uses thereof
#249Nuclear receptor ligands and ligand binding domains
#250Db, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
#251Prostaglandin receptor EP1
#252Use of cytokine receptors as biomarkers and therapeutic targets in human cancer
#253Retinoid X receptor-interacting polypeptides and related molecules and methods
#254WSX receptor agonist antibodies
#255Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion
#256Galanin receptor 2 proteins and nucleic acids
#257Assay employing human or rat GAL-R2 galanin receptor
#258Methods for assaying expression of novel galanin receptors
#259DB, the receptor for leptin, nucleic acids encoding the receptor, and uses thereof
#260Rhesus monkey Nur77
#261Compositions and methods involving glucocorticoid receptor site II
#262Transgenic mice containing lymphoid-specific GPCR gene disruptions
#263Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
#264Bacterial ligand-binding sensor
#265Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
#266Transgenic mice containing adrenocorticotropin hormone receptor gene disruptions
#267Natriuretic compounds, conjugates, and uses thereof
#268Transgenic mice containing melanocyte stimulating hormone receptor gene disruptions
#269Transgenic mice containing, cGMP phosphodiesterase gene disruptions
#270DNA encoding galanin receptor activating peptide
#271Transgenic mice containing sulfotransferase gene disruptions
#272Variants of corticotropin releasing hormone receptor type 1 and uses thereof
#273Human prostaglandin FP receptor variants and methods of using same
#274Methods for the identification of compounds for the treatment of Alzheimer's disease
#275Prolactin receptor gene as a genetic marker for increased litter size in animals
#276Natriuretic compounds, conjugates, and uses thereof
#277Recombinant bifunctional protein of human lutropin receptor and human chorionic gonadotropin B-subunit and uses thereof
#278Method for determining MIF content
#279Screening method and anti-tumor drug candidate obtained therefrom
#280Pael receptor, cells and animal expressing pael receptor and method of screning remedy for parkinson's disease
#281Receptors and signalling proteins capable of binding meiotic acting sterols (MAS)
#282Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
#283Methods for detection of the Ob receptor and the diagnosis of body weight disorders, including obesity and cachexia
#284Mutations of the 5' region of the human 5-HT1A gene, associated proteins of the 5' region and a diagnostic test for major depression and related mental illnesses
#285Modulation of growth hormone receptor expression and insulin-like growth factor expression
#286Non-mammalian GnRH analogs and uses thereof in regulation of fertility and pregnancy
#287Antibodies to insulin-like growth factor I receptor
#288Methods for treating obesity by inhibiting expression of obese gene product receptor variant
#289Controlling availability or activity of proteins by use of protease inhibitors or receptor fragments
#290Antibodies to insulin-like growth factor I receptor
#291Monopegylated growth hormone proteins
#292Screening methods using a novel human EP prostaglandin receptor
#293Polypeptides, their production and use
#294Use of monocarboxylate transporter protein for thyroid hormone transport
#295Prostaglandin receptor protein and methods of use thereof
#296Modified growth hormone fusion polypeptides
#297Human prostaglandin DP receptor variants and methods of using same
#298Human prostaglandin EP4 receptor variants and methods of using same
#299Human prostaglandin EP1 receptor variants and methods of using same
#300Novel cell-surface estrogen receptor and related compositions and methods